Sage Therapeutics, Inc. (NASDAQ:SAGE – Get Free Report) has been given a consensus rating of “Hold” by the eighteen analysts that are currently covering the firm, MarketBeat.com reports. Fifteen investment analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $43.78.
SAGE has been the subject of a number of research analyst reports. HC Wainwright cut their target price on Sage Therapeutics from $50.00 to $27.00 in a research report on Tuesday, August 8th. Canaccord Genuity Group downgraded Sage Therapeutics from a “buy” rating to a “hold” rating and cut their target price for the stock from $64.00 to $21.00 in a research report on Tuesday, August 8th. Bank of America cut their target price on Sage Therapeutics from $25.00 to $24.00 and set a “neutral” rating for the company in a research report on Friday, September 8th. Truist Financial cut their price objective on Sage Therapeutics from $40.00 to $20.00 and set a “hold” rating for the company in a research report on Tuesday, August 8th. Finally, TD Cowen cut their price objective on Sage Therapeutics from $105.00 to $28.00 and set an “outperform” rating for the company in a research report on Tuesday, August 8th.
Institutional Trading of Sage Therapeutics
Sage Therapeutics Price Performance
SAGE opened at $19.72 on Tuesday. The company has a market capitalization of $1.18 billion, a price-to-earnings ratio of -1.80 and a beta of 1.12. Sage Therapeutics has a 1-year low of $16.51 and a 1-year high of $59.99. The business has a 50 day moving average price of $19.61 and a two-hundred day moving average price of $33.26.
About Sage Therapeutics
Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; zuranolone, a neuroactive steroid, which has completed Phase III clinical trials for treating PPD and major depressive disorders, as well as is in Phase II clinical trials for treatment resistant depression, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases.
- Five stocks we like better than Sage Therapeutics
- How to Invest in Semiconductors
- Safeguard your portfolio with these three bargain stocks
- Earnings Per Share Calculator: How to Calculate EPS
- Membership clubs gain leverage for the consumer rebound
- How Can Investors Benefit From After-Hours Trading
- Advanced Auto Parts may be worth more in pieces than the whole
Receive News & Ratings for Sage Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.